Tipos de propiedad

Principal Investigator:

Olli Kallioniemi, M.D., Ph.D., Director, Institute for

Molecular Medicine Finland (FIMM), University of Helsinki, Tukholmankatu 8, 00140 University of Helsinki, Finland. Director of the Academy of Finland Centre of Excellence on Translational Genome-scale Biology (2006-2011),

Medical Biotechnology, VTT Technical Research Centre of Finland and University of Turku.

Laboratory address: Medical Biotechnology, PharmaCity, Itäinen Pitkäkatu 4C, FI-20521 Turku, Finland. Tel. +358-20-722 2800. Fax +358-20-722 2840. E-mail: [email protected].

Biography:

Dr. Olli Kallioniemi received his M.D. in 1984 and Ph.D. in 1988 at the University of Tampere in Finland. Olli Kallioniemi held several positions in the US over a 10-year period, such as Head of Trans- lational Genomics Section at the Cancer Genetics Branch, National Human Genome Research Institute, at the NIH, Bethesda, Mary- land during 1995-2002. In 2003, he was appointed as Professor of Medical Biotechnology at the VTT Technical Research Centre of Finland with a joint appointment at the University of Turku. Acade- my of Finland Professor in 2004-2007. In 2007, he was nominated as a director of the Institute for Molecular Medicine Finland (FIMM), a Nordic EMBL Partnership in Molecular Medicine. He continues to direct the ongoing projects in Turku until the end of 2011. He is an author of 263 publications and editor or member of the edito- rial board of six journals. Inventor of 18 issued patents, with a fo- cus on technology development, such as Comparative Genomic Hybridization (CGH) in 1992, tissue microarrays in 1998 and cell- based RNAi microarrays in 2003. EACR young investigator award in 1994, Anders Jahre Prize in 1998, NIH Director’s lecture in 2000, Medal of the Swedish Medical Society in 2003, National Academy of Sciences (Finland) in 2005, EMBO Membership in 2006, and the Abbot-IFCC award in Molecular Diagnostics 2009.

Personnel:

Ph.D-students and postdocs at the University of Turku: Anna Aakula, M.Sc., Santosh Gupta, M.Sc., Kirsi Ketola, M.Sc., Pekka Kohonen, Ph.D. Paula Vainio, M.D., Sirkku Pollari, M.Sc., Techni- cians: Pirjo Käpylä, Coordinator: Terhi Jokilehto, M.Sc.

Description of the Project:

The overall purpose of this research program is to develop and apply high-throughput technologies to understand mechanisms of progression of breast and prostate cancers as well as to identify mechanisms of drug response.

1. Apply cancer genomics to identify key genes and pathways in

breast and prostate cancer

2. Apply high-throughput RNA interference and chemical biology

to identify living cells, with particular attention towards cancer- specific vulnerabilities and steroid-dependent signaling and

3. Translate the molecular discoveries towards drug discovery,

We use systems biology and chemical biology approaches to char- acterize the deregulation of cancer cell functions. The research is carried out in collaboration between the Institute for Molecular Medicine Finland (FIMM), the Medical Biotechnology Centre of the VTT Technical Research Centre of Finland and the Turku Centre for Biotechnology. Our group coordinates Academy of Finland Centre of Excellence in Translational Genome-Scale Cell Biology. We have developed and are applying biochip technologies, next-generation RNA sequencing, bioinformatics, systems biology, drug develop- ment technologies, cell microarrays, protein lysate microarrays, in silico profiling of gene expression in clinical samples and many others.

Collaborators:

Tomi Mäkelä, Lauri Aaltonen, Jussi Taipale, Päivi Ojala, Sampsa Hautaniemi, Heli Nevanlionna, Heikki Joensuu, Kari Alitalo, Jona- than Knowles, Emmy Verschuren, Sergey Kuznetshov, Samuli Ripatti, Krister Wennerberg (FIMM and Biomedicum Helsinki), Antti Poso, Samuel Kaski, Tapio Visakorpi, Jukka Westermarck and many others in other Universities in Finland. We have over 100 partners in EU-FP7 collaborative projects such as Epitron, Genica, APO-SYS, Prosper, Meta-Cancer and Systems Microscopy.

Funding:

The Academy of Finland, Tekes, Finnish Cancer Organizations and Sigrid Juselius Foundation. Our biggest source of funding comes from the EU framework projects.

Selected recent publications:

Mpindi JP, Sara H, Haapa-Paananen S, Kilpinen S, Pisto T, Bu- cher E, Ojala K, Iljin K, Vainio P, Björkman M, Gupta S, Kohonen P, Nees M, Kallioniemi O. GTI: A Novel Algorithm for Identifying Out- lier Gene Expression Profiles from Integrated Microarray Datasets. PLoS One. 2011 Feb 18;6(2):e17259.

Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomark- ers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011 Mar;8(3):142-50.

Ostling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perälä M, Kallioniemi O. Systematic Analysis of MicroRNAs Tar- geting the Androgen Receptor in Prostate Cancer Cells. Cancer Res. 2011 Mar 1;71(5):1956-1967. Epub 2011 Feb 22.

Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, Fey V, Perälä M, Smit F, Verhaegh G, Schalken J, Alanen KA, Kallioniemi O, Iljin K. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic tar- gets in prostate cancer. Am J Pathol. 2011 Feb;178(2):525-36. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol. 2011 Jan 19;12(1):R6.

Kilpinen S, Ojala K, Kallioniemi O. Analysis of kinase gene expres- sion patterns across 5681 human tissue samples reveals func- tional genomic taxonomy of the kinome. PLoS One. 2010 Dec

3;5(12):e15068. From left to right, first row: Paula Vainio, Mari Björkman, Riina Plosila, Pekka Kohonen, Back row: Kirsi Ketola, Anna Aakula, Santosh Gupta, Olli Kallioniemi, Sirkku Pollari, Elmar Bucher.

Rantala JK, Edgren H, Lehtinen L, Wolf M, Kleivi K, Vollan HK, Aaltola AR, Laasola P, Kilpinen S, Saviranta P, Iljin K, Kallioniemi O. Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia. 2010 Nov;12(11):877-88.

Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010 Sep 1;70(17):6735-45. Epub 2010 Aug 16.

Härmä V, Virtanen J, Mäkelä R, Happonen A, Mpindi JP, Knuuttila M, Kohonen P, Lötjönen J, Kallioniemi O, Nees M. A comprehen- sive panel of three-dimensional models for studies of prostate can- cer growth, invasion and drug responses. PLoS One. 2010 May 3;5(5):e10431.

International Cancer Genome Consortium, Hudson TJ,et al. Inter- national network of cancer genome projects. Nature. 2010 Apr 15;464(7291):993-8.

Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogene- sis. Breast Cancer Res Treat. 2011 Jan;125(2):421-30. Epub 2010 Mar 30.

Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale AL, Saviranta P, Perälä M, Kallioniemi O. Pro- tein lysate microarray analysis to identify microRNAs regulating es- trogen receptor signaling in breast cancer cell lines. Oncogene, 28(44):3926-3936, 2009.

Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Graf- ström RC, Perälä M, Kallioniemi O. High-throughput cell- based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate can- cer cell growth. Clin Cancer Res., 15(19):6070-6078, 2009. Varjosalo M, Björklund M, Cheng F, Syvänen H, Kivioja T, Kil- pinen S, Sun Z, Kallioniemi O, Stunnenberg HG, He, W-W, Ojala P, Taipale J. Application of Active and Kinase-Defi- cient Kinome Collection for Identification of Kinases Reg- ulating Hedgehog Signaling. Cell, 133:537-548, 2008. Pellinen T, Tuomi S, Arjonen A, Wolf M, Edgren H, Meyer H, Ran- tala JK, Kallioniemi O, Fässler R, Kallio M and Ivaska J. Integrin traffic regulated by Rab21 is necessary for cytokinesis. Dev. Cell., 15(3):371-385, 2008.

Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, Saa- rela M, Skotheim R, Björkman M, Mpindi J. P., Haapa-Paananen S, Vainio P, Edgren H, Wolf M, Astola J, Nees M, Hautaniemi S, Kal- lioniemi Olli. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol., 9(9):R139, 2008.

SIGNALING PATHWAYS REGULATED